How BioMarin Turned a Competitive Threat Into a Royalty-Bearing Asset

BioMarin (BMRN) reached a settlement with Ascendis (ASND) that turns the Yuviwel patent fight into a royalty stream: Ascendis will pay BioMarin royalties of 20% of U.S. net sales and 18% of EU/Brazil/South Korea sales from first commercial sale through May 20, 2030 (with U.S. royalties retroactive to the first sale). Yuviwel posted €8M in Q2 2026 revenue and has 220+ enrolled patients with 65%+ reimbursed, improving near-term commercialization visibility. While this partially offsets Voxzogo sales risk, the competitive threat remains as BridgeBio (BBIO) targets a potential mid-2027 U.S. launch of an oral achondroplasia therapy.

Analysis

This is less a clean win for the incumbent than a conversion of an existential IP threat into a toll road. The key market mechanism is that BioMarin has traded binary injunction risk for a recurring royalty stream, which should stabilize near-term sentiment and reduce discount-rate pressure on BMRN’s achondroplasia franchise. That said, royalties are a hedge, not a moat: if the competitor’s convenience advantage drives adoption, BioMarin still loses the higher-margin direct sale and only captures a fraction of the economics.

The second-order effect is that the settlement likely improves the commercial legitimacy of the competing product rather than suppressing it. Removing litigation noise can help payer access, physician comfort, and launch velocity, which means the royalty stream may ramp faster than the market expects while Voxzogo share erosion also accelerates. For ASND, the royalty burden is a meaningful tax on U.S./EU economics, but it also removes a costly legal overhang and de-risks expansion; that makes the stock less attractive on standalone margin optics, but not necessarily on probability-weighted launch success.

The bigger structural threat is still the next entrant. If an oral achondroplasia therapy gets approved, the market could shift from a two-product incremental share battle to a convenience-led re-rating of the category, which would pressure BioMarin’s terminal revenue assumptions more than current models imply. Net: BMRN is tactically better on reduced litigation risk, but the stock likely needs proof that royalty income outpaces Voxzogo decay; otherwise this is only a temporary cushion, not a durable growth inflection.

Key Decisions for Investors

• Long BMRN / short BBIO over 3-6 months: BMRN now monetizes the near-term competitor, while BBIO remains the cleaner upside/downside binary on the next wave of achondroplasia disruption; use the pair as a relative-value hedge against category growth rather than single-name beta.
• Sell/underweight ASND on strength after the settlement-driven rally: the market may be underpricing the royalty drag on long-term economics; thesis breaks if Yuviwel prescription growth accelerates without a corresponding margin reset or reimbursement friction.
• Buy BMRN on any post-news pullback for a tactical 1-3 month trade, but only if Voxzogo monthly script data remains stable; stop if there is a >10% sequential decline in new patient starts or if management guides to erosion that exceeds royalty offset.
• Set a watch item on BBIO’s FDA path and launch timing for mid-2027: approval would be the real structural catalyst that can overwhelm the current royalty thesis and compress BMRN’s premium P/S multiple.